Articles with "treated nivolumab" as a keyword



Photo from wikipedia

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Thoracic Oncology"

DOI: 10.1016/j.jtho.2017.10.030

Abstract: Objective The aim of this study was to identify baseline peripheral blood biomarkers associated with clinical outcome in patients with NSCLC treated with nivolumab. Methods Univariable and multivariable analyses were performed retrospectively for 134 patients… read more here.

Keywords: outcome; peripheral blood; biomarkers associated; treated nivolumab ... See more keywords
Photo from wikipedia

High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy.

Sign Up to like & get
recommendations!
Published in 2023 at "Journal of gastroenterology and hepatology"

DOI: 10.1111/jgh.16239

Abstract: BACKGROUND Nivolumab extends the overall survival (OS) of patients with advanced gastric cancer (AGC). Intramuscular adipose tissue (IMAT) is associated with the prognosis of patients with various cancers. We investigated the effect of IMAT on… read more here.

Keywords: treated nivolumab; survival; advanced gastric; patients advanced ... See more keywords
Photo from wikipedia

Sclerosing cholangitis in a patient treated with nivolumab

Sign Up to like & get
recommendations!
Published in 2021 at "BMJ Case Reports"

DOI: 10.1136/bcr-2021-241700

Abstract: A 69-year-old retired miner with stage 4 non-small-cell lung cancer presented with a 2-month history of obstructive liver function tests following nivolumab immunotherapy. His case had not responded to high dose prednisolone or mycophenolate and… read more here.

Keywords: patient treated; cholangitis; cholangitis patient; sclerosing cholangitis ... See more keywords
Photo by tcooper86 from unsplash

Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab

Sign Up to like & get
recommendations!
Published in 2022 at "BMJ Case Reports"

DOI: 10.1136/bcr-2022-251233

Abstract: Nivolumab is an immune checkpoint inhibitor acting on programmed cell death protein 1 (PD-1) that has been used to treat a growing number of malignancies. Cutaneous side effects are common with nivolumab treatment, though they… read more here.

Keywords: patient treated; treated nivolumab; lichenoid dermatitis; johnson syndrome ... See more keywords
Photo by nci from unsplash

Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study

Sign Up to like & get
recommendations!
Published in 2022 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2022-004885

Abstract: Background The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a ‘real-world setting’. We conducted a translational-research program to determine… read more here.

Keywords: treated nivolumab; cell; soluble factors; within nivoren ... See more keywords
Photo from wikipedia

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay

Sign Up to like & get
recommendations!
Published in 2023 at "Therapeutic Advances in Medical Oncology"

DOI: 10.1177/17588359231151845

Abstract: Individual response to immune checkpoint inhibitors (ICIs) is currently unpredictable in patients with melanoma. Recent findings highlight a striking improvement in the clinical outcomes of overweight/obese patients treated with ICIs, which seems driven, at least… read more here.

Keywords: treated nivolumab; nivolumab pembrolizumab; role; patients treated ... See more keywords
Photo by nci from unsplash

Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.e16077

Abstract: e16077 Background: Body mass index (BMI) and inflammation indexes are easily evaluated, predict survival in many tumors, and are potentially modifiable. The "obesity paradox" of longer survival in cancer patients with high BMI has been… read more here.

Keywords: treated nivolumab; cell; bmi; body mass ... See more keywords
Photo from wikipedia

Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab

Sign Up to like & get
recommendations!
Published in 2022 at "Cancer Management and Research"

DOI: 10.2147/cmar.s382771

Abstract: Background There is a need to develop biomarkers for a more efficient use of immune checkpoint inhibitors (ICIs). Recently, it has been reported that peripheral blood components, including eosinophils, may be effective ICI biomarkers. This… read more here.

Keywords: treated nivolumab; head neck; metastatic head; squamous cell ... See more keywords
Photo from wikipedia

Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab.

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of the College of Physicians and Surgeons--Pakistan : JCPSP"

DOI: 10.29271/jcpsp.2022.10.1288

Abstract: OBJECTIVE To evaluate the utility of inflammatory prognostic index (IPI), albumin, c-reactive protein (CRP), and lactate dehydrogenase (LDH) as predictive biomarkers of oncologic outcome in metastatic renal cell cancer (mRCC) patients treated with nivolumab. STUDY… read more here.

Keywords: treated nivolumab; ipi; metastatic renal; analysis ... See more keywords